knowledge -WSS

knowledge

author：explore 2025-10-02 00:42:45 - browse：3389

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： CDC Director Mandy Cohen on transparency, trust, and health

WSS

CVS Caremark has created a new ploy: the drug ‘rebate credit’

The haunting brain science of long Covid

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Asbestos, a deadly carcinogen, banned by EPA

New lawsuit accuses health insurer Cigna of denying claims in bulk

Biogen says it will cut costs by $700 million, slash 1,000 jobs

focus

knowledge

Wikipedia

Jerome Adams on the need for new antivirals for Covid

SCOTUS questions limit to govt efforts to fight misinformation

Medical leaders decry Supreme Court decision on affirmative action

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Medical records are filled with copy

Virtual Event: March of the Biosimilars

Heart attack and stroke risk calculators need revising

Why patients can’t get everything they want on drug pricing

23andMe had bad news about my health. I wish a person had delivered it

SCOTUS questions limit to govt efforts to fight misinformation

Wikipedia

Leading voice in opioid treatment defends methadone clinic system

Biden warns of ‘dark winter’ during final presidental debate

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Intermittent fasting comes with a heart risk? Not so fast

What to watch for from Zogenix and Amicus clinical trials

App could help diagnose ear infections more accurately — and at home

leisure time

entertainment

entertainment

focus